Overview
UTHR market data
Price History
UTHR price chart · 1M
- O
- 515.58
- H
- 521.29
- L
- 514.44
- C
- 516.70
- Vol
- 19,575.00
- Source
- US equities market feed
- Observed
- Aug 26, 2026, 12:00 AM
- Cadence
- Five-minute page cache; daily and stored hourly bars
- Status
- fresh
Key Stats & Performance
- Open
- $515.58
- Previous Close
- $518.62
- Day High
- $521.29
- Day Low
- $514.44
- 52 Week High
- $608.70
- 52 Week Low
- $471.29
- 7 Day Return
- -2.40%
- 30 Day Return
- -1.98%
- 90 Day Return
- -8.04%
- 1 Year Return
- +8.06%
- Daily Notional Volume
- $10.1M Latest daily bar volume multiplied by its closing price.
Valuation & Profitability
- P/E (TTM)
- 17.03 Trailing twelve-month price-to-earnings ratio. Higher means the market is pricing in more growth. Negative or missing when earnings are negative.
- Forward P/E
- — P/E based on consensus forward EPS estimates. Lower versus trailing implies expected earnings growth.
- EPS (TTM)
- $27.86 Diluted earnings per share over the trailing twelve months.
- Beta
- 0.50 Volatility relative to the index. 1.00 equals market, above 1 amplifies the broad-market move, below 1 dampens it.
- Dividend Yield
- — Annual dividend per share divided by current price. Zero or blank when the company does not pay a dividend.
- Profit Margin
- 41.6% Net income divided by revenue. Comparable within a sector, less so across sectors.
- 52w range
- $302.19 – $609.35 Lowest and highest closing prices over the past 52 weeks.
- Analyst Target
- — Mean of sell-side analyst 12-month price targets. Use as a sentiment gauge; targets are biased upward in aggregate.
Display-only. Refreshed once per symbol per 24 hours · market cap $22.3B · P/B 2.96 · P/S 7.08.
Company News
United Therapeutics Announces FDA Accepted NDA For Ralinepag In Pulmonary Arterial Hypertension, With PDUFA Target Action Date Of June 24, 2027Benzinga · Aug 24, 2026, 1:28 PM
United Therapeutics Announces Full Enrollment Of TETON-PPF Study Evaluating Use Of Tyvaso Inhalation Solution For Treatment Of Progressive Pulmonary Fibrosis; Topline Data Expected In H2 Of 2027Benzinga · Aug 17, 2026, 11:11 AM
RBC Capital Maintains Outperform on United Therapeutics, Lowers Price Target to $677Benzinga · Aug 6, 2026, 5:57 PM
8-K filing — UNITED THERAPEUTICS Corp (UTHR)SEC EDGAR · Aug 5, 2026, 10:33 AM
United Therapeutics Q2 EPS $7.27 Beats $6.88 Estimate, Sales $783.300M Miss $805.645M EstimateBenzinga · Aug 5, 2026, 10:30 AM
United Therapeutics Announces Publication of ADVANCE OUTCOMES Study in The Lancet; Ralinepag Remains Investigational for PAHBenzinga · Jul 29, 2026, 10:37 AM
United Therapeutics CEO Sells $5 Million of Shares. What Does This Mean for Investors?The Motley Fool · Jul 28, 2026, 10:15 PM
JP Morgan Maintains Overweight on United Therapeutics, Raises Price Target to $687Benzinga · Jul 23, 2026, 6:47 PM
B of A Securities Maintains Neutral on United Therapeutics, Lowers Price Target to $613Benzinga · Jul 10, 2026, 6:10 PM
BETA Completes First FAA eIPP Electric Aircraft Flights, Transporting Manufactured Organs For United TherapeuticsBenzinga · Jul 10, 2026, 4:40 PM